Results from a Phase 3 study regarding Actemra (tocilizumab) found the prescription medication was effective in the treatment of early aggressive rheumatoid arthritis among patients who have not received methotrexate, according to MedPage Today.


Study investigator Dr. Gerd R. Burmester of Charite-Universitatsmedizin in Berlin noted a significant number of patients (45 percent) receiving intravenous Actemra 8mg/kg once monthly plus methotrexate achieved remission at week 24 compared to those given placebo plus methotrexate (15 percent).


Click here to read more